Prevalence of drug resistance mutations and HIV type 1 subtypes in an HIV type 1-infected cohort in Rural Tanzania

AIDS Research and Human Retroviruses

Volumn 29, Issue 9, 2013, Pages 1229-1236

  Masimba, Pax ^a,b   Kituma, Elimsaada ^a,b   Klimkait, Thomas ^b   Horvath, Edit ^a,c   Stoeckle, Marcel ^b   Hatz, Christoph ^a,b   Mossdorf, Erick ^a   Mwaigomole, Emmanuel ^c,d   Khamis, Salim ^c,d   Jullu, Boniphace ^c   Abdulla, Salim ^c   Tanner, Marcel ^a,b   Felger, Ingrid ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c IFAKARA HEALTH INSTITUTE   (Tanzania)

^d St Francis Designated District Hospital   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; PHYLOGENY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RURAL AREA; SINGLE NUCLEOTIDE POLYMORPHISM; TANZANIA; TREATMENT FAILURE; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENETIC VARIATION; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE HYDROLASES; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, VIRAL; TANZANIA;

EID: 84882990480     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0367     Document Type: Article

References (22)

1. Arroyo MA, Hoelscher M, Sateren W, et al.: HIV-1 diversity and prevalence differ between urban and rural areas in the Mbeya region of Tanzania. AIDS 2005;19. Available at http://journals.lww.com/aidsonline/Fulltext/2005/09230/ HIV-1-diversity-and-prevalence-differ-between.11.aspx.
2. Autran B, Carcelain G, Li TS, et al.: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277: 112-116.
3. Ledergerber B, Egger M, Opravil M, et al.: Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Lancet 1999;353:863-868.
4. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, and Detours V: Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001;58:19-42.
5. Hemelaar J, Gouws E, Ghys PD, and Osmanov S: Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006;20:W13-W23.
6. Geretti AM, Harrison L, Green H, et al.: Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis 2009;48: 1296-1305.
7. Kiwanuka N, Laeyendecker O, Robb M, et al.: Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 2008;197:707-713.
8. National AIDS Control Programme M of H and SW of the UR of T: National Guidelines for the Management of HIV and AIDS, 2005. Available at www.nacp.go.tz/modules/doc-sm/docs-by-type.php?tbltype-doctype = Guidelines.
9. TACAIDS, 2008. 2011. Available at www.tacaids.go.tz/strategic-documents/ facts-and-figures-statistics.html. Accessed 20 July 2011.
10. TACAIDS, 2008. Available at www.tacaids.go.tz/strategicdocuments/facts- and-figures-statistics.html. Accessed 20 July 2011.
11. UNGASS/TACAIDS, 2010. Available at www.unaids.org/en/dataanalysis/ monitoringcountryprogress/2010progress reportssubmittedbycountries/tanzania- 2010-country-progress-report-en.pdf. Accessed 20 July 2011.
12. Nyombi B, Holm-Hansen C, Kristiansen K, Bjune G, and Muller F: Prevalence of reverse transcriptase and protease mutations associated with antiretroviral drug resistance among drug-naive HIV-1 infected pregnant women in Kagera and Kilimanjaro regions, Tanzania. AIDS Res Ther 2008;5:13.
13. Arroyo MA, Hoelscher M, Sanders-Buell E, et al.: HIV type 1 subtypes among blood donors in the Mbeya region of southwest Tanzania. AIDS Res Hum Retroviruses 2004;20: 895-901.
14. Mossdorf E, Stoeckle M, Mwaigomole E, et al.: Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition. BMC Infect Dis 2011;11:98.
15. Mossdorf E, Stoeckle M, Vincenz A, et al.: Impact of a national HIV voluntary counselling and testing (VCT) campaign on VCT in a rural hospital in Tanzania. Trop Med Int Health 2010;15:567-573.
16. Mosha F, Urassa W, Aboud S, et al.: Prevalence of genotypic resistance to antiretroviral drugs in treatment-naive youths infected with diverse HIV type 1 subtypes and recombinant forms in Dar es Salaam, Tanzania. AIDS Res Hum Retroviruses 2011;27:377-382.
17. Svicher V, Ceccherini-Silberstein F, Erba F, et al.: Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. Antimicrob Agents Chemother 2005;49:2015-2025.
18. Chaturbhuj DN, Hingankar NK, Srikantiah P, et al.: Transmitted HIV drug resistance among HIV-infected Voluntary Counseling and Testing Centers (VCTC) clients in Mumbai, India. AIDS Res Hum Retroviruses 2010;26:927-932.
19. Nyombi BM, Kristiansen KI, Bjune G, Müller F, and Holm-Hansen C: Diversity of human immunodeficiency virus type 1 subtypes in Kagera and Kilimanjaro regions, Tanzania. AIDS Res Hum Retroviruses 2008;24:761-769.
20. Morison L, Buvé A, Zekeng L, et al.: HIV-1 subtypes and the HIV epidemics in four cities in sub-Saharan Africa. AIDS 2001;15(Suppl 4):S109-116.
21. Stoeckle M, Mchomvu R, and Hatz C: Moving up from 3 by 5. Lancet Infect Dis 2006;6:460-461.
22. Baxter JD, Schapiro JM, Boucher CAB, et al.: Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 2006;80: 10794-10801.